Trial Outcomes & Findings for Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19). (NCT NCT04898166)
NCT ID: NCT04898166
Last Updated: 2021-10-26
Results Overview
Outcome of participants suffering from covid-19 with respect to age group as better outcomes: oxygen mask/bag or nasal cannula Worst outcomes: ventilator or death
Recruitment status
COMPLETED
Target enrollment
300 participants
Primary outcome timeframe
From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months
Results posted on
2021-10-26
Participant Flow
300 participants at COVID-19 isolation unit jinnah postgraduate medical centre karachi.
* 300 participants signed consent for participation. * 300 participants assigned for the study.
Participant milestones
| Measure |
220 Hospitalized Male Participants Diagnosed Case of COVID-19.
220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
80 Hospitalized Female Participants Diagnosed Case of COVID-19.
80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
|---|---|---|
|
Overall Study
STARTED
|
220
|
80
|
|
Overall Study
COMPLETED
|
220
|
80
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).
Baseline characteristics by cohort
| Measure |
220 Hospitalized Male Participants Diagnosed Case of COVID-19.
n=220 Participants
220 hospitalized male Participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
80 Hospitalized Female Participants Diagnosed Case of COVID-19
n=80 Participants
80 hospitalized female Participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
Total
n=300 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
53.39 years
STANDARD_DEVIATION 14.928 • n=93 Participants
|
52.17 years
STANDARD_DEVIATION 8.391 • n=4 Participants
|
53.06 years
STANDARD_DEVIATION 13.5 • n=27 Participants
|
|
Age, Customized
Between 20 to 40 years
|
41 Participants
n=93 Participants
|
29 Participants
n=4 Participants
|
70 Participants
n=27 Participants
|
|
Age, Customized
Between >40 to 60 years
|
99 Participants
n=93 Participants
|
51 Participants
n=4 Participants
|
150 Participants
n=27 Participants
|
|
Age, Customized
>60 years
|
80 Participants
n=93 Participants
|
00 Participants
n=4 Participants
|
80 Participants
n=27 Participants
|
|
Sex: Female, Male
Female
|
00 Participants
n=93 Participants
|
80 Participants
n=4 Participants
|
80 Participants
n=27 Participants
|
|
Sex: Female, Male
Male
|
220 Participants
n=93 Participants
|
00 Participants
n=4 Participants
|
220 Participants
n=27 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
00 Participants
n=93 Participants
|
00 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
220 Participants
n=93 Participants
|
80 Participants
n=4 Participants
|
300 Participants
n=27 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
00 Participants
n=93 Participants
|
00 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
|
Region of Enrollment
Pakistan
|
220 Participants
n=93 Participants
|
80 Participants
n=4 Participants
|
300 Participants
n=27 Participants
|
|
Comorbidities
Smoking
|
14 Participants
n=93 Participants
|
2 Participants
n=4 Participants
|
16 Participants
n=27 Participants
|
|
Comorbidities
Ischemic heart disease
|
12 Participants
n=93 Participants
|
4 Participants
n=4 Participants
|
16 Participants
n=27 Participants
|
|
Comorbidities
Diabetes mellitus
|
35 Participants
n=93 Participants
|
17 Participants
n=4 Participants
|
52 Participants
n=27 Participants
|
|
Comorbidities
Hypertension
|
34 Participants
n=93 Participants
|
17 Participants
n=4 Participants
|
51 Participants
n=27 Participants
|
|
Comorbidities
Obesity
|
15 Participants
n=93 Participants
|
6 Participants
n=4 Participants
|
21 Participants
n=27 Participants
|
|
Comorbidities
Chronic kidney disease
|
10 Participants
n=93 Participants
|
5 Participants
n=4 Participants
|
15 Participants
n=27 Participants
|
|
Comorbidities
Multiple comorbidities
|
20 Participants
n=93 Participants
|
19 Participants
n=4 Participants
|
39 Participants
n=27 Participants
|
|
Comorbidities
No comorbidity
|
82 Participants
n=93 Participants
|
10 Participants
n=4 Participants
|
92 Participants
n=27 Participants
|
PRIMARY outcome
Timeframe: Day 1 of admissionFrequency of Androgenetic alopecia in patients be noted.
Outcome measures
| Measure |
220 Hospitalized Participants Diagnosed Case of COVID-19.
n=220 Participants
220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19
n=80 Participants
80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
|---|---|---|
|
Androgenetic Alopecia Frequency in Participants.
With androgenetic alopecia
|
209 Participants
|
37 Participants
|
|
Androgenetic Alopecia Frequency in Participants.
Without androgenetic alopecia
|
11 Participants
|
43 Participants
|
PRIMARY outcome
Timeframe: Day 1 of admissionSeverity of androgenetic alopecia be measured using Hamilton and norwood scale (HNS) less than 3 or 3-7. In females using ludwig scale: less than 2 or 2-3. Hamilton norwood score: Minimum value 1, maximum value 7. Ludwig score: minimum 0, maximum 3 Mild to moderate: HNS \<3/ Ludwig \<2 Severe: HNS 3-7/ ludwig 2-3
Outcome measures
| Measure |
220 Hospitalized Participants Diagnosed Case of COVID-19.
n=220 Participants
220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19
n=37 Participants
80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
|---|---|---|
|
Severity of Androgenetic Alopecia in Patients
Mild to moderate
|
43 Participants
|
9 Participants
|
|
Severity of Androgenetic Alopecia in Patients
Severe
|
177 Participants
|
28 Participants
|
PRIMARY outcome
Timeframe: Day 1 of admissionAge of the patient is very important to co-relate with disease outcome and severity of Androgenetic alopecia
Outcome measures
| Measure |
220 Hospitalized Participants Diagnosed Case of COVID-19.
n=300 Participants
220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19
80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
|---|---|---|
|
300 Participants Mean Age
|
53.06 years
Standard Deviation 13.495
|
—
|
PRIMARY outcome
Timeframe: From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 monthsOutcome of participants suffering from covid-19 with respect to age group as better outcomes: oxygen mask/bag or nasal cannula Worst outcomes: ventilator or death
Outcome measures
| Measure |
220 Hospitalized Participants Diagnosed Case of COVID-19.
n=220 Participants
220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19
n=80 Participants
80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
|---|---|---|
|
Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.
Participants on mask/bag with age 20-40years
|
15 Participants
|
10 Participants
|
|
Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.
Participants on mask/bag with age >40-60 years
|
13 Participants
|
18 Participants
|
|
Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.
Participants on mask/bag with age >60years
|
13 Participants
|
0 Participants
|
|
Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.
Participants on Nasal cannula with age 20-40years
|
15 Participants
|
4 Participants
|
|
Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.
Participants on nasal cannula with age >40-60 years
|
37 Participants
|
12 Participants
|
|
Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.
Participants on nasal cannula with age >60years
|
20 Participants
|
0 Participants
|
|
Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.
Participants on ventilator with age 20-40years
|
4 Participants
|
11 Participants
|
|
Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.
Participants on ventilator with age >40-60 years
|
16 Participants
|
15 Participants
|
|
Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.
Participants on ventilator with age >60years
|
10 Participants
|
0 Participants
|
|
Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.
Participants death with age 20-40 years
|
7 Participants
|
4 Participants
|
|
Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.
Participants death with age >40-60 years
|
33 Participants
|
6 Participants
|
|
Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.
Participants death with age >60years
|
37 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 monthsCovid-19 disease outcome assessed by Severity of androgenetic alopecia to find out their correlation
Outcome measures
| Measure |
220 Hospitalized Participants Diagnosed Case of COVID-19.
n=220 Participants
220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19
80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
|---|---|---|
|
Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males
Patients on nasal cannula with HNS <3
|
20 Participants
|
—
|
|
Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males
Patients on nasal cannula with HNS 3-7
|
52 Participants
|
—
|
|
Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males
Patients on mask/bag with HNS <3
|
14 Participants
|
—
|
|
Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males
Patients on mask/bag with HNS 3-7
|
27 Participants
|
—
|
|
Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males
Patients on ventilator with HNS <3
|
5 Participants
|
—
|
|
Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males
Patients on ventilator with HNS 3-7
|
25 Participants
|
—
|
|
Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males
Patients death with HNS <3
|
4 Participants
|
—
|
|
Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males
Patients death with HNS 3-7
|
73 Participants
|
—
|
PRIMARY outcome
Timeframe: From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 monthsCovid-19 disease outcome assessed by Severity of androgenetic alopecia to find out their correlation
Outcome measures
| Measure |
220 Hospitalized Participants Diagnosed Case of COVID-19.
n=80 Participants
220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19
80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
|---|---|---|
|
Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females
Female participants on mask/bag with no androgenetic alopecia
|
9 Participants
|
—
|
|
Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females
Female participants on mask/bag with ludwig scale <2
|
3 Participants
|
—
|
|
Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females
Female participants on mask/bag with ludwig scale 2-3
|
4 Participants
|
—
|
|
Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females
Female participants on nasal cannula without androgenetic alopecia
|
17 Participants
|
—
|
|
Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females
Female participants on nasal cannula with ludwig scale <2
|
3 Participants
|
—
|
|
Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females
Female participants on nasal cannula with ludwig scale 2-3
|
8 Participants
|
—
|
|
Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females
Female participants on ventilator with no androgenetic alopecia
|
14 Participants
|
—
|
|
Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females
Female participants on ventilator with ludwig scale <2
|
3 Participants
|
—
|
|
Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females
Female participants on ventilator with ludwig scale 2-3
|
9 Participants
|
—
|
|
Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females
Female participants death with no androgenetic alopecia
|
3 Participants
|
—
|
|
Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females
Female participants death with ludwig scale <2
|
0 Participants
|
—
|
|
Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females
Female participants death with ludwig scale 2-3
|
7 Participants
|
—
|
PRIMARY outcome
Timeframe: From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 monthsIt is to find out how severily disease outcomes can be affected due to androgeneic alopecia by age accordingly.
Outcome measures
| Measure |
220 Hospitalized Participants Diagnosed Case of COVID-19.
n=37 Participants
220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19
n=43 Participants
80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
|---|---|---|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.
Age 20-40yrs: nasal cannula
|
0 Participants
|
4 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.
Age >40-60yrs: nasal cannula
|
7 Participants
|
5 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.
Age >60yrs nasal cannula
|
00 Participants
|
00 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.
Age 20-40yrs: mask/bag
|
3 Participants
|
7 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.
Age >40-60yrs: mask/bag
|
8 Participants
|
10 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.
Age >60yrs mask/bag
|
00 Participants
|
00 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.
Age 20-40yrs: ventilator
|
6 Participants
|
5 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.
Age >40-60yrs: ventilator
|
6 Participants
|
9 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.
Age >60yrs: ventilator
|
00 Participants
|
00 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.
Age 20-40yrs: death
|
3 Participants
|
1 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.
Age >40-60yrs: death
|
4 Participants
|
2 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.
Age >60yrs: death
|
00 Participants
|
00 Participants
|
PRIMARY outcome
Timeframe: From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 monthsIt is to find out how severily disease outcomes can be affected due to androgeneic alopecia by age accordingly.
Outcome measures
| Measure |
220 Hospitalized Participants Diagnosed Case of COVID-19.
n=43 Participants
220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19
n=177 Participants
80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
|---|---|---|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males
Nasal cannula Age 20-40yrs
|
4 Participants
|
11 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males
Nasal cannula age >40-60yrs
|
10 Participants
|
27 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males
Nasal cannula age >60yrs
|
6 Participants
|
14 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males
Mask/bag age 20-40yrs
|
6 Participants
|
9 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males
Mask/bag age >40-60yrs
|
5 Participants
|
8 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males
Mask/bag age >60yrs
|
3 Participants
|
10 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males
Ventilator age 20-40yrs
|
1 Participants
|
3 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males
Ventilator age >40-60yrs
|
2 Participants
|
14 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males
Ventilator age >60yr
|
2 Participants
|
8 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males
Death age 20-40yrs
|
0 Participants
|
7 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males
Death age >40-60yrs
|
1 Participants
|
32 Participants
|
|
Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males
Death age >60yrs
|
3 Participants
|
34 Participants
|
PRIMARY outcome
Timeframe: Disease outcome during this 4 month duration of study.Hospital disease outcome as mask, cannnula, ventilator or death in 300 subjects. Having 220 males and 80 Females
Outcome measures
| Measure |
220 Hospitalized Participants Diagnosed Case of COVID-19.
n=220 Participants
220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19
n=80 Participants
80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
|---|---|---|
|
Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females
Mask/bag
|
41 Participants
|
28 Participants
|
|
Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females
Nasal cannula
|
72 Participants
|
16 Participants
|
|
Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females
Ventilator usage
|
30 Participants
|
26 Participants
|
|
Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females
Death
|
77 Participants
|
10 Participants
|
SECONDARY outcome
Timeframe: Date of randomization until upto 4 monthsComorbidities in patients suffering from covid-19 is of great value as it affects disease outcome.number of patients suffrring from comorbidities eg: diabetes mellitus, smoking, hypertension, ischemic heart disease, chronic kidney disease, obesity.
Outcome measures
| Measure |
220 Hospitalized Participants Diagnosed Case of COVID-19.
n=300 Participants
220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19
80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
|---|---|---|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
Participants death with no comorbidity
|
26 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant death with history of smoking
|
1 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant death: history of ischemic heart disease
|
9 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant death with history diabetes mellitus
|
18 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant death with history of hypertension
|
18 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant death with history of obesity
|
1 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant death with history of kidney disease
|
5 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant death with history of multiple comorbidities
|
9 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on nasal cannula with no comorbidity
|
29 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on nasal cannula with history of smoking
|
6 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on nasal cannula with history of ischemic heart disease
|
4 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on nasal cannula with history of diabetes mellitus
|
12 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on nasal cannula with history of hypertension
|
15 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on nasal cannula with history of obesity
|
8 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on nasal cannula with history of chronic kidney disease
|
5 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on nasal cannula with history of multiple comorbidities
|
9 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on mask/bag with no comorbidity
|
20 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
Participants on mask/bag with history of smoking
|
6 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on mask/bag with history of history of ischemic heart disease
|
1 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on mask/bag with history of diabetes mellitus
|
15 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on mask/bag with history of hypertension
|
8 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on mask/bag with obesity
|
6 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on mask/bag with history of chronic kidney disease
|
4 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on mask/bag with history of multiple comorbidities
|
9 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on ventilator with no comorbidity
|
17 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
Participants on Ventilator with history of smoking
|
1 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on ventilator with history of ischemic heart disease
|
2 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on ventilator with history of diabetes mellitus
|
7 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on ventilator with history of hypertension
|
10 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on ventilator with history of obesity
|
6 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on Ventilator with history of chronic kidney disease
|
1 Participants
|
—
|
|
Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants
participant on ventilator with history of multiple comorbidities
|
12 Participants
|
—
|
SECONDARY outcome
Timeframe: Day 1 of admission, till disease outcome in upto 4 monthsDuration of symptoms patients experiencing from the onset of symptoms till outcome.
Outcome measures
| Measure |
220 Hospitalized Participants Diagnosed Case of COVID-19.
n=300 Participants
220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19
80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
|---|---|---|
|
Disease Duration of COVID-19
|
11.79 Days
Standard Deviation 5.727
|
—
|
Adverse Events
300 Participants Diagnosed Case of Hospitalized COVID-19 With or Without Androgenetic Alopecia.
Serious events: 300 serious events
Other events: 0 other events
Deaths: 87 deaths
Serious adverse events
| Measure |
300 Participants Diagnosed Case of Hospitalized COVID-19 With or Without Androgenetic Alopecia.
n=300 participants at risk
300 Participants diagnosed case of hospitalized COVID-19. 220 males and 80 females. Presence or absence of androgenetic alopecia be noted in males and females. Severity of androgeneic throught be noted throught Hamilton norwood score and ludwig score, respectively. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.
|
|---|---|
|
Infections and infestations
87 male and female participants death
|
29.0%
87/300 • From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condition(from mask/bag to ventilator) or death from any cause, assessed up to 4 months
Our participants are hospitalized COVID-19 patients. Their adverse events are categorised as on oxygen mask/bag,nasal cannula, ventilator or death. Other non serious adverse events are zero because all of our participants were having covid19 so they faced it's symptom and no any other adverse event separately
|
|
Infections and infestations
Male and female participants on ventilator
|
18.7%
56/300 • From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condition(from mask/bag to ventilator) or death from any cause, assessed up to 4 months
Our participants are hospitalized COVID-19 patients. Their adverse events are categorised as on oxygen mask/bag,nasal cannula, ventilator or death. Other non serious adverse events are zero because all of our participants were having covid19 so they faced it's symptom and no any other adverse event separately
|
|
Infections and infestations
Male and female participants on oxygen mask/bag
|
23.0%
69/300 • From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condition(from mask/bag to ventilator) or death from any cause, assessed up to 4 months
Our participants are hospitalized COVID-19 patients. Their adverse events are categorised as on oxygen mask/bag,nasal cannula, ventilator or death. Other non serious adverse events are zero because all of our participants were having covid19 so they faced it's symptom and no any other adverse event separately
|
|
Infections and infestations
Male and female participants on nasal cannula
|
29.3%
88/300 • From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condition(from mask/bag to ventilator) or death from any cause, assessed up to 4 months
Our participants are hospitalized COVID-19 patients. Their adverse events are categorised as on oxygen mask/bag,nasal cannula, ventilator or death. Other non serious adverse events are zero because all of our participants were having covid19 so they faced it's symptom and no any other adverse event separately
|
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place